These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23572013)

  • 21. High levels of viral load monitoring and viral suppression under Treat All in Rwanda - a cross-sectional study.
    Ross J; Ribakare M; Remera E; Murenzi G; Munyaneza A; Hoover DR; Shi Q; Nsanzimana S; Yotebieng M; Nash D; Anastos K;
    J Int AIDS Soc; 2020 Jun; 23(6):e25543. PubMed ID: 32536033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting.
    Geng EH; Hare CB; Kahn JO; Jain V; Van Nunnery T; Christopoulos KA; Deeks SG; Gandhi M; Havlir DV
    Clin Infect Dis; 2012 Dec; 55(12):1690-7. PubMed ID: 22955429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.
    Coffey S; Bacchetti P; Sachdev D; Bacon O; Jones D; Ospina-Norvell C; Torres S; Lynch E; Camp C; Mercer-Slomoff R; Lee S; Christopoulos K; Pilcher C; Hsu L; Jin C; Scheer S; Havlir D; Gandhi M
    AIDS; 2019 Apr; 33(5):825-832. PubMed ID: 30882490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102.
    Henry K; Katzenstein D; Cherng DW; Valdez H; Powderly W; Vargas MB; Jahed NC; Jacobson JM; Myers LS; Schmitz JL; Winters M; Tebas P;
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):140-8. PubMed ID: 16760795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
    Staszewski S; Miller V; Sabin C; Schlecht C; Gute P; Stamm S; Leder T; Berger A; Weidemann E; Hill A; Phillips A
    AIDS; 1999 May; 13(8):951-6. PubMed ID: 10371176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the care cascade after antiretroviral therapy initiation in Latin America.
    Wolff MJ; Cortes CP; Mejìa FA; Padgett D; Belaunzarán-Zamudio P; Grinsztejn B; Giganti MJ; McGowan CC; Rebeiro PF;
    Int J STD AIDS; 2018 Jan; 29(1):4-12. PubMed ID: 28618980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.
    Caby F; Guihot A; Lambert-Niclot S; Guiguet M; Boutolleau D; Agher R; Valantin MA; Tubiana R; Calvez V; Marcelin AG; Carcelain G; Autran B; Costagliola D; Katlama C
    Clin Infect Dis; 2016 May; 62(10):1297-1303. PubMed ID: 26908792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
    Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
    J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term immune and virological response in HIV-infected patients receiving antiretroviral therapy.
    Silveira MP; Silveira CP; Guttier MC; Page K; Moreira LB
    J Clin Pharm Ther; 2016 Dec; 41(6):689-694. PubMed ID: 27676134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.
    Hughes AJ; Mattson CL; Scheer S; Beer L; Skarbinski J
    J Acquir Immune Defic Syndr; 2014 May; 66(1):80-9. PubMed ID: 24326608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
    Wood E; Hogg RS; Yip B; Tyndall MW; Sherlock CH; Harrigan RP; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):159-66. PubMed ID: 12045678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort.
    Lesko CR; Tong W; Moore RD; Lau B
    AIDS Behav; 2017 Apr; 21(4):1016-1024. PubMed ID: 27752872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.
    Byakwaga H; Murray JM; Petoumenos K; Kelleher AD; Law MG; Boyd MA; Emery S; Mallon PW; Cooper DA
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):756-76. PubMed ID: 19500017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].
    ;
    Enferm Infecc Microbiol Clin; 2007 Jan; 25(1):32-53. PubMed ID: 17261244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retention in care is more strongly associated with viral suppression in HIV-infected patients with lower versus higher CD4 counts.
    Yehia BR; French B; Fleishman JA; Metlay JP; Berry SA; Korthuis PT; Agwu AL; Gebo KA;
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):333-9. PubMed ID: 24129370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
    Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
    JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
    Afrane AKA; Goka BQ; Renner L; Yawson AE; Alhassan Y; Owiafe SN; Agyeman S; Sagoe KWC; Kwara A
    BMC Infect Dis; 2021 Aug; 21(1):731. PubMed ID: 34340689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System.
    Horberg MA; Hurley LB; Klein DB; Towner WJ; Kadlecik P; Antoniskis D; Mogyoros M; Brachman PS; Remmers CL; Gambatese RC; Blank J; Ellis CG; Silverberg MJ
    AIDS Patient Care STDS; 2015 Nov; 29(11):582-90. PubMed ID: 26505968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.